Drilldown: Medicines
Medicines > classes 
:
Dissociative or
[[:Category:Glucocorticoids|Glucocorticoid (intermediate-acting)]]
:
Dissociative or
[[:Category:Glucocorticoids|Glucocorticoid (intermediate-acting)]] Use the filters below to narrow your results.
generic:
None (1) ·
2-FDCK (1) ·
3-HO-PCE (1) ·
3-HO-PCP (1) ·
3-MeO-PCE (1) ·
3-MeO-PCP (1) ·
4-MeO-PCP (1) ·
Deschloroketamine (1) ·
Dextromethorphan (1) ·
Dextrorphan (1) ·
Diphenidine (1) ·
Ephenidine (1) ·
Eticyclidine (1) ·
Ibogaine (1) ·
Methoxetamine (1) ·
Methylprednisolone (1) ·
Nitrous oxide (1) ·
O-PCE (1) ·
Prednisolone (and prednisolone sodium phosphate, acetate, etc.) (1) ·
Prednisone (1) ·
Salvia divinorum (1) ·
Salvinorin A (1) ·
Triamcinolone (acetonide and other esters) (1) ·
Xenon (1)
brand:
None (17) ·
Deltasone, Rayos (delayed-release); mostly prescribed generically (1) ·
DXM (1) ·
DXO (1) ·
Kenalog (injectable), Nasacort (intranasal), Aristocort (topical), Trianex (1) ·
Medrol (oral), Solu-Medrol (IV/IM), Depo-Medrol (depot injection) (1) ·
Prelone, Pediapred, Orapred ODT, Millipred, Veripred (1) ·
Spravato (1)
classes: (Click arrow to add another value)
mechanism:
None (3) ·
Active metabolite of DXM; NMDA antagonist (1) ·
Contains salvinorin A (1) ·
Kappa-opioid agonist; NMDA antagonist; SERT/DAT/NET inhibitor (1) ·
Kappa-opioid receptor agonist (1) ·
NMDA antagonist (3) ·
NMDA antagonist; endogenous opioid releaser (1) ·
NMDA antagonist; fluorinated ketamine analogue (1) ·
NMDA antagonist; kappa-opioid agonist (1) ·
NMDA antagonist; ketamine analogue (1) ·
NMDA antagonist; more stimulating than PCP (1) ·
NMDA antagonist; opioid agonist (1) ·
NMDA antagonist; potent opioid agonist (1) ·
NMDA antagonist; SERT inhibitor; sigma-1 agonist (1) ·
NMDA antagonist; sigma receptor agonist (2) ·
NMDA antagonist; sigma receptor agonist; dopaminergic (1) ·
NMDA antagonist; sigma-1 agonist; serotonin reuptake inhibitor (1) ·
'"`UNIQ--vote-00000860-QINU`"' Activates the glucocorticoid receptor to broadly remodel inflammatory, immune, and metabolic transcription. Unlike prednisone, it does not require hepatic activation, making it the preferred oral choice in severe hepatic dysfunction'"`UNIQ--ref-00000861-QINU`"'. (1) ·
'"`UNIQ--vote-000008BE-QINU`"' Preferred over prednisone in advanced hepatic dysfunction where hepatic 11β-HSD1 activation is impaired. Liquid formulations are the workhorse pediatric oral corticosteroid for asthma and croup'"`UNIQ--ref-000008BF-QINU`"'. (1)
uses:
None (19) ·
Treatment-resistant depression (TRD) in adults, as adjunct to oral antidepressant (FDA-approved March 2019). Depressive symptoms in adults with MDD with acute suicidal ideation or behavior (FDA-approved Aug 2020). (1) ·
'"`UNIQ--vote-0000029D-QINU`"', '"`UNIQ--vote-0000029E-QINU`"', '"`UNIQ--vote-0000029F-QINU`"', '"`UNIQ--vote-000002A0-QINU`"', '"`UNIQ--vote-000002A1-QINU`"', '"`UNIQ--vote-000002A2-QINU`"' (1) ·
'"`UNIQ--vote-00000661-QINU`"', '"`UNIQ--vote-00000662-QINU`"', '"`UNIQ--vote-00000663-QINU`"', '"`UNIQ--vote-00000664-QINU`"', '"`UNIQ--vote-00000665-QINU`"' (1) ·
'"`UNIQ--vote-00000862-QINU`"', '"`UNIQ--vote-00000863-QINU`"', '"`UNIQ--vote-00000864-QINU`"', '"`UNIQ--vote-00000865-QINU`"', '"`UNIQ--vote-00000866-QINU`"' (1) ·
'"`UNIQ--vote-000008C0-QINU`"', '"`UNIQ--vote-000008C1-QINU`"', '"`UNIQ--vote-000008C2-QINU`"', '"`UNIQ--vote-000008C3-QINU`"' (1)
starting dose:
None (19) ·
0.5-2 mg/kg/d divided or single morning dose for acute conditions; lowest effective dose for chronic conditions, with planned taper (1) ·
Induction (TRD): 56 mg intranasal twice weekly × 4 weeks. Maintenance: 56-84 mg once weekly × 4 weeks, then 56-84 mg every 1-2 weeks. For acute suicidality: 84 mg twice weekly × 4 weeks. Administered under medical supervision in REMS-certified site. (1) ·
Pediatric 1-2 mg/kg/d (max 60 mg) PO for asthma exacerbation; adult dosing similar to prednisone milligram-for-milligram (~1:1 potency) (1) ·
PO Medrol Dosepak (5-day taper from 24 mg to 4 mg) is the prototypic short-course outpatient regimen; IV pulse 1 g daily for 3-5 days for MS relapse; intra-articular 4-80 mg per joint q1-5 weeks (1) ·
Topical 0.025-0.5% cream/ointment BID; intra-articular 5-40 mg per joint q3-6 months; intranasal Nasacort 110 mcg/spray, 2 sprays/nostril daily; oral paste 0.1% to lesion 2-3×/d (1)
preparations:
None (19) ·
1, 2.5, 5, 10, 20, 50 mg tablets; 5 mg/5 mL syrup; 5 mg/mL concentrate (1) ·
2, 4, 8, 16, 32 mg oral tablets; 40, 125, 500, 1000 mg IV vials; Depo-Medrol 20, 40, 80 mg/mL IM depot (1) ·
28 mg/device (each dose uses 2 devices) (1) ·
5 mg tablets; 5 mg/5 mL, 10 mg/5 mL, 15 mg/5 mL oral solutions (sweetened pediatric); 5 mg/5 mL syrup; ophthalmic 0.12%, 1% suspensions and 1% solution (1) ·
Topical creams, ointments, lotions, dental paste (0.025-0.5%); Kenalog 10 mg/mL, 40 mg/mL injection; Nasacort 55 mcg/spray intranasal; oral inhaler discontinued in US (1)
fda max:
routes:
None (19) ·
IM (2) ·
intra-articular (2) ·
intralesional (1) ·
intramuscular (1) ·
intranasal (1) ·
Intranasal (under direct medical supervision) (1) ·
intrathecal (rare and controversial) (1) ·
IV (1) ·
IV (prednisolone sodium phosphate) (1) ·
ophthalmic (1) ·
Oral (3) ·
oral paste (1) ·
Topical (1)
onset:
duration:
None (19) ·
Acute effect ~24 hours; cumulative effect builds with repeated dosing (1) ·
Biologic 12-36 hours (intermediate-acting) (1) ·
Biologic 12-36 hours (intermediate-acting); Depo-Medrol depot weeks (1) ·
Biologic half-life ~12-36 hours (intermediate-acting); plasma half-life shorter (1) ·
Intra-articular 3-6 months (depot effect of acetonide microcrystals) (1)
halflife:
None (19) ·
Plasma 2-3 hours; biologic ~18-36 hours'"`UNIQ--ref-00000867-QINU`"' (1) ·
Plasma 2-3 hours; biologic ~18-36 hours'"`UNIQ--ref-000008C4-QINU`"' (1) ·
Plasma 3-4 hours; biologic ~12-36 hours'"`UNIQ--ref-000002A3-QINU`"' (1) ·
Plasma ~3-5 hours; biologic effect substantially longer (~12-36 hours for intermediate-acting glucocorticoids)'"`UNIQ--ref-00000666-QINU`"' (1) ·
~7-12 hours (1)
bioavailability:
None (19) ·
70-80% (oral)'"`UNIQ--ref-000002A4-QINU`"' (1) ·
Topical/intranasal: high local, low systemic; intra-articular: local depot then systemic absorption'"`UNIQ--ref-00000667-QINU`"' (1) ·
~48% intranasal (1) ·
~70% (oral)'"`UNIQ--ref-000008C5-QINU`"' (1) ·
~80-99% (oral)'"`UNIQ--ref-00000868-QINU`"' (1)
pregnancy:
None (19) ·
Avoid; may cause fetal harm (1) ·
Topical/intranasal generally low-risk; intra-articular and high-dose injection: weigh risk individually.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Use when benefits outweigh; small association with oral clefts debated.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Use when benefits outweigh; small association with oral clefts in first trimester debated.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Used when benefits outweigh risk; oral cleft signal in first-trimester exposure is debated and small in absolute terms.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
Showing below up to 24 results in range #1 to #24.